# Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

> **NCT06613841** · EARLY_PHASE1 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 15 (estimated)

## Conditions studied

- Glioblastoma
- Recurrent Glioblastoma
- Glioblastoma Multiforme of Brain

## Interventions

- **DRUG:** Fluciclovine F18

## Key facts

- **NCT ID:** NCT06613841
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613841, "Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06613841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*